Positron Corporation a leading molecular imaging company specializing in the field of nuclear cardiology, announced the introduction of its automated radiopharmaceutical system, under the name PosiRx, at two upcoming industry conferences. PosiRx is the commercial name for the company’s automated radiopharmaceutical system, formerly referred to as Cardio-Assist during its developmental stage.
Positron’s PosiRx system is a radiopharmaceutical system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging. Positron will introduce its PosiRx system at the upcoming American Pharmacists Association Annual Meeting and Exposition, March 25-28, in Seattle, Washington and at the American College of Cardiology April 2-5, in New Orleans, Louisiana.
“Products such as the PosiRx will be critical in revolutionizing, simplifying and controlling procedures associated with the compounding, dispensing and distributing of radiopharmaceuticals, resulting in increased productivity, and decreased exposure and costs.”
“PosiRx offers capabilities that enhance each segment of the value chain from pharmaceutical manufacturers, pharmacy’s and ultimately the physician practice or hospital whereby improving the efficiency, economics, availability and safety of radiopharmaceutical preparation,” said Patrick G. Rooney, CEO of Positron.
The company noted the current focus of Positron’s PosiRx will be handling technetium 99m SPECT imaging agents which supports Positron’s overall strategy of simplifying and improving radiopharmaceutical dose preparation and delivery. The PosiRx system provides molecular imaging departments with 24/7 unit dose accessibility, combined with the reliability of an on-site supply, and assists in compliance with all current USP-797 requirements for the production of unit dose radiopharmaceuticals.
Positron Corporation provides unique solutions for the Nuclear Medicine community through the production and distribution of molecular imaging devices and radiopharmaceutical products.